Author + information
- Yi Li,
- Shaoyi Guan,
- Mingzi Guan,
- Xiaozeng Wang,
- Jing Li,
- Heyang Wang,
- Yong Huo,
- Frans Van de Werf,
- Jie Jiang,
- Ana Maria Vega,
- Nobuya Hayashi and
- Yaling Han
Background: The long-term use of antiplatelet agents (APs) after acute coronary syndrome (ACS) in diabetic patients is not well known. Here, we describe AP use and outcomes in diabetic patients with ACS from the EPICOR Asia registry.
Methods: EPICOR Asia (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients in Asia, NCT01361386) is a prospective, observational study of 12,922 ACS patients surviving to discharge with 2-y follow up, from 8 countries in Asia. Diabetic and non-diabetic patients were matched by propensity scores. The impact of diabetes on use of APs and events (composite of death, myocardial infarction [MI], and stroke ± any revascularization; individual components, and bleeding) were evaluated using chi-square test and log-rank test, respectively.
Results: Among 3079 matched-patient pairs, demographic and baseline characteristics were generally well-balanced between diabetic and non-diabetic patients. Use of APs at discharge were similar between the 2 groups, most patients receiving DAPT (∼90%). At 2-y, slightly more diabetic patients still received DAPT (60% vs 57%). Diabetic patients were at increased risk from ischemic events but diabetes had minimal impact on risk of bleeding events (Table).
Conclusions: AP use is comparable at discharge and on long-term follow up in diabetic and non-diabetic patients. Diabetic patients are at increased risk of ischemic events suggesting an unmet need for improved antithrombotic treatment.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome
Abstract Category: 2. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number: 1204-345
- 2017 American College of Cardiology Foundation